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■ Abstract   
 
Fungal infections reduce the quality of life for 1.7 billon individuals worldwide killing 
approximately 1.6 million people every year. Candidemia is one of the most common 
fungal infections in humans, established from pathogenic Candida species. About 
65% of candidemia cases arise from the commensal C. albicans. Emergence of 
resistance to current antifungal drugs is growing concern. The Kent Fungal Group 
has recently identified an organism named Yeast Killer Fungus (Resinicium bicolor). 
The novel YKF secrets a compound that demonstrates desirable traits for a 
promising antifungal agent.  
The aim of this Research Project is twofold: firstly, to characterise the antifungal 
bioactivity of the YKF compound; and secondly, to utilise biochemical approaches 
in order to identify the YKF compound. 
Firstly, a protocol was established to routinely test the antifungal properties of the 
YKF compound. During this experiment, it was determined that a fresh YKF culture 
supernatant (s/n) reaches its full potential at 14 days when stored at optimal 20-
22°C, room temperature. In comparison, YKF s/n stored in 4-5°C temperature 
reached maximum antifungal strength after 34 days. Suggesting room temperature 
YKF antifungal compound deteriorates faster. Results presented in this thesis 
demonstrate that the YKF s/n inhibits the cellular growth of C. albicans and other 
Candida species including the emerging multi-drug resistant C. auris pathogen. 
Importantly, results presented in this thesis strongly indicate that the YKF compound 
if fungicidal agent as it is able to kill C. albicans cells. This is key as current antifungal 
drugs are mainly fungistatic, halting microbial growth. Mass spectroscopy analysis 
[3] 
 
showed that the YKF compound had close extract spectra with tomatidine, a 
component synthesised by the tomato plant. However, the nature of the YKF 
compound still remains unknown.  
In conclusion, YKF expresses a strong susceptibility towards a broad range of 
Candida species and suitable fungicidal characteristics. Very beneficial for a future 
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1. Fungal infections: A overview 
Fungi are eukaryotic organisms found ubiquitously worldwide. Fungi exist in nature 
in various ways in, plant form or as microorganisms parasitizing in mammalians. 
However, several fungal species are pathogenic very few of those are primary 
pathogens in humans [1]. As a consequence, fungal pathogens cause sever disease 
in individuals that are experiencing advance stages of serious illnesses when their 
immune system is suppressed. In the recent years, fungal related diseases have 
risen significantly [1-3]. Present estimate indicates that nearly 1.7 billion people are 
affected, 300 million of those are more serious in nature leading to approximately 
1.6 million deaths to occur annually [1-3]. The global health impact consists of high 
morbidity and mortality of 30-80%, in addition, to the economic implications 
presiding a multibillion pounds economic liability per year [1-5].  
Fungal infections manifest in two pathological forms, superficial and invasive, also 
commonly referred as systematic, fungal infection. Superficial fungal infections 
(SFIs) are defined when the pathogenic fungi are located in the stratum corneum, 
known as the epidermis or, the skin outer layer [6]. These dermatophyte infections 
are considered as localised infections that regularly occur among all ages, sex, and 
global dispersal. These fungal infections are easier to treat and cause less 
discomfort for the patient. Good personal hygiene in concert with antifungal drug 
therapy is the usual successful treatment for superficial infections [7].  
On the other hand, invasive fungal infections (IFIs) are more challenging to treat 
and are regarded as a critical world health concern. IFIs are considered those yeast 
[12] 
 
infections that colonise internally, generalised, visceral, and sever life-threatening 
infections that commonly occur in immune-compromised individuals [8]. IFIs due to 
antifungal treatment proceed to chronically manifestation internally in humans and 
as such are consistently regarded as systemic infections [8].  
Currently, invasive fungal infections are among the most challenging clinically 
administered infections in humans. The total mortality for individuals experiencing 
IFIs is as high as 45% in a global range [9-10]. Invasive fungal infections occur most 
frequently in immunocompromised individuals, and less frequently in healthy 
individuals [11]. Accordingly, the success of novel advanced treatments in cancer 
care, haematopoietic stem cell (HSC) or organ transplant procedures, neonatal or 
autoimmune disease therapy, HIV/AIDS infection, and surgery, put these categories 
of individuals at a significantly high risk [12]. In many instances, such treatment 
therapies can be the leading cause of fungal infection in the first place [11]. Mortality 
rate for IFIs individuals remains at high-level although several antifungal drugs are 
largely available [1][3][5]. Such elevated mortality levels often exceed deaths 
caused by tuberculosis and malaria [5][13-14]. Therefore, pinpointing to the 
significance of investigating fungal related diseases, their main component and 
antifungal therapy.  
 
2. Candida species role in fungal infections  
Mammalian species, and especially humans, are home to one of the most crucial 
fungal microorganisms to be intensively studied the Candida species. These 
ubiquitous species belong to the polyphyletic fungal order of Saccharomycotina [15]. 
[13] 
 
The Candida family are generally harmless commensal microorganisms which are 
predominantly found to colonise the mucous membrane in humans.  
2.1. The Candida family members 
Candida species are a diverse family of fungal organisms with very distinct 
evolutionary phylogenesis. Candida albicans are the most populous of the Candida 
species which live as a commensal in the human body but turns pathogenic due to 
genetic or environmental factors. C. albicans together with Candida dubliniensis are 
of the same species groups and along together with C. tropicalis and Candida 
parapsilosis belong to the same clade called Candida. Candida guilliermondii, also 
known as Meyerozyma guillermondii, are the next closest relative as they all belong 
to the Debaryomycetaceae taxonomic family. C. auris are the next nearest fungal 
relatives to the Debaryomycetaceae family members [16-17]. These Candida 
species belong to the CTG clade where the CUG codon amino acids leucine to 
serine are reassigned [18-19]. C. krusei (or Pichia kudriavzevii), are the most distant 
relative to Candida genus members [16-17]. C. glabrata is the furthest fungi species 
related to any of the organisms belonging to the Candida species. C. glabrata is a 
closer fungal relative to the simple yeasting bud Saccharomyces cerevisiae (S. 
cerevisiae) and belongs to the WGD (whole-genome duplication) clade [18-19]. C. 
krusei and C. glabrata are the only of the Candida species that do not belong to 
CTG clade. The taxonomic illustration of the most clinically relevant Candida family 




    
Fig. 1, The phylogeny of Candida species involved in candidemia. Squared in 
red are the Candida species used on this thesis. Most of the Candida, including C. 
albicans belong to the CTG Debaryomycetaceae clade. C. glabrata and C. krusei, 




2.2. Cellular biology of Candida species 
Candida species are genera of a diverse fungal kingdom. Candida are 
ascomycetous-like fungal species where most family members are anamorphic [20]. 
Candida species, when grown in laboratory environment, display round, relatively 
large in shape, in a white to light yellow colour [21]. C. albicans, named as such 
from the Latin word albico for “whiten” or “becoming white” are the most studied and 
pervasive fungal pathogen in humans. C. albicans undergo a diploid life cycle and 
express a wide-ranging variety of morphological phenotypes due to their ability to 
phenotypical switch and transitional switch from yeast bud to other forms [21-22].  
2.2.1. Yeast-to-hyphae switch    
The C. albicans and other Candida species are grown as round, ovoid, shaped 
fungal organisms. The morphological yeast-to-hyphae disfiguration arises by 
various external stimuli as seen in Figure 2. The environmental promoters 
investigated to cause hyphae development are: a temperature increase of above 
37°C, carbon and/or nitrogen starvation, reduced oxygen, elevated levels of carbon 
dioxide, change in pH, increasing cell density during quorum sensing, and 
generation of N-acetylglucosamine (GlcNAc) [23-24]. Furthermore, pathogenic C. 
albicans undergo the filamentous hyphal cell change either outside or inside the 
host bloodstream. This hyphal change is extensively suggested to contribute 
towards the fungal virulence [25]. C. tropicalis and C. dubliniensis are also known 
to undergo the yest-to-hyphae transformation but on more limited environmental 
conditions range [26]. Recent studies also suggest the C. auris also forms hyphae, 
however, unlike C. albicans and other closely phylogenetic related Candida, only do 




Fig. 2, A simple schematic representation of the environmental stimuli that 
lead to the filamentous hyphae phenomena. The outer factors interfere with 
cellular mediators which activate transcriptional changes. The alternation cause in 
turn the development of hyphal morphological properties. However, certain 
molecular processes are still not fully understood.  
 
2.2.2. Yeast-to-opaque switch    
The other significant morphological change that happens to C. albicans is white-to 
opaque switch. The opaque cells adopt a darker colour, growing larger and 
elongated cells, and express an opaque specific set of genes [28]. The structural 
switch is suggested to occur primarily as a result of transcriptional regulators, 
however, the full molecular mechanisms for the switch state are not fully understood 
[28]. The key component on this process is the C. albicans mating cycle. The 
transcriptional factors encode the Mating Type Like (MTL) locus referred to as, a/α 
[29-30]. This process, demonstrated on Figure 3, occurs when a/α cells under 
homozygosis mating leading to a/a and α/α cells hence prompting white-to-opaque 
[17] 
 
switch to arise [31]. MTL-homozygous a/a and α/α cells mate only with those cells 
that exhibit the opaque phenotype [21][32]. The white-to-opaque switch is directed 
by the WOR1 (White to Opaque Regulator 1) protein [33]. The phenotypic switches 
occur spontaneously as a result of environmental, epigenetic, or other additional 




Fig. 3, The white-to-opaque switch of C. albicans operated by the MTL. The 
diploid C. albicans when mate generate a a/α cell tetraploid. To return to the diploid 
state the cell must undergo loss of chromosome thereby no conventional meiosis 
does not occurred. The MTL process causes the cell switch and a large darker oval 
cell is produced. For a cell mating with α cells is possible but both have to be in 
structural opaque for this to happen.  
 
2.3. The clinical manifestation of Candidemia  
Candida species specifically reside on human gastrointestinal (GI) and 
genitourinary (GU) tracts [15]. However, as mentioned, in immunocompromised 
[18] 
 
individuals Candida species become pathogenic organisms. Patients undergoing 
intensive care such as, chemotherapy, HSC, or organ transplantation, Candida 
organisms can cause mouth and oesophagus infections. In patients undergoing 
chemotherapy Candida microorganisms are transmitted via the intestinal epithelium 
membrane thereby heavily affecting the liver and spleen. These organs are both 
effected as they are connected through portal circulation [34]. HIV infected 
individuals are also significantly influenced by pathogenic Candida organisms, 
resulting, to circulatory infections [35-36]. In healthy women, pathogenic Candida 
species severely affect the reproductive organs causing vaginitis [35-36]. 
Candidemia, in the early 2000s, was determined to be the fourth most common 
nosocomial infection in the USA, causing over 10,000 deaths annually as a result of 
Candida species infections [35-39].  
Most of candidemia cases, as mentioned, are related to C. albicans. The majority of 
individuals worldwide carry C. albicans as harmless commensal microorganism 
inhabiting the mucosa membrane [40]. The evolutionary process of C. albicans 
gives them the ability to refuge and live in intense conditions within the human 
microenvironment. They colonise the high pH intestine, benefiting from the 
anaerobic and high supply nutrient of the GI tract or reside on the low pH vaginal 
system, profiting from glycogen resources and aerobic environment [41-44]. C. 
albicans rapidly adapt to different locations, mainly to the evolutionary ability to go 
unnoticed by human immune system macrophages. C. albicans avoid interaction 
with dectin-1 receptor on the macrophage using glycoproteins to hide β-1-3-D-
glucan in its cell wall [45]. C. albicans are one of many other fungi that reside as 
commensals in the human organism but on a pathogenic form infect and cause 
challenging diseases.  
[19] 
 
Furthermore, candidemia in approximately 92% of cases has been caused by 
members of Candida species. C. albicans account for most of Candida caused 
candidemia at 65.3%, C. glabrata are responsible for 11.3%, C. tropicalis for 7.2%, 
C. parapsilosis accounts for 6%, and 2.4% of cases arise because C. krusei (Figure 
4) [46]. The other most common organisms, C. guillermondii only account for 0.7% 
of candidemia incidents. A new emerging fungus is C. auris, first, reported in 2008 
in Pakistan and then named in 2009 by Satoh et al. from investigations collected on 
fungal-infected patients in Japan [47][48]. C. auris, as a recently recognized fungi, 
based on various studies suggest prevalence in candidemia is uncertain as it is 
globally spread with highest number of reported cases in India, the UK, Spain, and 
the New York State in the US [16]. In comparative studies C. auris has shown to be 
less virulent than C. albicans but trends of higher mortality rate [49-53]. In contrast 
to other Candida species, C. auris can successfully spread to other nosocomial 
environments [54]. C. auris is able to reside in such environments due to its 
capability to form biofilms and has proved to be difficult to kill even with high-levels 
of disinfectant treatment [54-55]. 
 
The incidence frequency of Candida species isolates differs based on patient 
characteristics such as, age or ongoing disease, and geographical location. C. 
albicans and C. parapsilosis are predominantly observed in younger individuals and 
their infection prevalence decreases with age. In comparison, C. glabrata 
prevalence in candidemia infected patients increased with older age [56]. 
Underlaying disease is also a factor in for the advancement of candidemia. C. 
albicans are indicated to be the primary cause of candidemia in oncology and 
haematology related cases, respectively 51% and 33% of precedence [57]. 
[20] 
 
Furthermore, C. krusei related infections are expressed in Europe and North 
America, 3.4% and 3.1% respectively, whereas C. glabrata is more common in 
North America, accounting for 21% of the candidemia infected individuals. C. 
tropicalis is over-represented in Latin America, at 13.2%, and Pacific Asia, at 11.7%, 
in comparison, C. guillermondii is expressed in 2.2% of the cases in Latin America 
[4][46]. Candida species are a diverse family of yeast that holds responsibility for 
IFIs at various ages and geographical position.   
 
 
Fig. 4, Candidemia infection prevalence per Candida species. C. albicans are 
involved in approximately 65% of all Candidemia related infections. The yeast C. 
glabrata accounts for a considerable prevalence in Candidemia cases at about 11%. 





3. Current antifungal drug treatment 
There are numerous antifungal drugs available for fungal infections. Azole and 
echinocandins are the two main antifungal class of drugs.  
3.1. Azole class family  
Azoles are the largest family of antifungal drugs. Azole drugs inhibit the sterols 
biosynthesis enzyme lanosterol 14 α-demethylase, seen on Figure 5, which 
prevents the biosynthesis of the fungal cell membrane ergosterol [58]. Analogous to 
the animal cell cholesterol, ergosterol is the largest fungal cell membrane sterol 
agent. The efficacy of azoles as antifungals relates to the sufficient morphological 
differences of human cholesterol and fungal ergosterol. Thus, azole antifungal target 
does not biosynthetically cross-react with the human host cells. The azole family is 
categorised in three groups the triazoles, like fluconazole; the imidazoles, including 
ketoconazole; and the itraconazole hydroxylated analogue, posaconazole (Table 1) 
[59]. The azole drugs block 14 α-lanosterol demethylase a cytochrome P450-
dependent enzyme, encoded by ERG11 gene. In the cell membrane lanosterol is 
converted to ergosterol by the ERG11 gene consequently inhibits the growth and 
replication of the fungi [60].  
3.2. Echinocandins class family  
Echinocandins are the second largest family of antifungal drugs. Echinocandins are 
the newest class of antifungal drugs available, shown on Table 1 [61]. Caspofungin, 
micrafungin and anidulafungin were identified in the 1970s however took 30 years 
to be approved. The caspofungin drug was only approved in 2001 and is the only 
novel antifungal class of drug to gain approval in the 21st century [62]. The 
membrane-bound glucosyltransferase enzyme, β-(1,3)-D-glucan synthase forms 
[22] 
 
more than half of the cell fungal cell well components and is the prime structural 
polysaccharide for glycoproteins, chitins and other cell wall agents attach [63]. 
Therefore, echinocandins lipopeptidic agents, particularly target fungal wall enzyme 
β-(1,3)-D-glucan synthase inhibiting its function, presented on Figure 5. This prevent 
the establishment of the crucial cell wall polysaccharide component β-(1,3)-D-
glucan, necessary for cell wall integrity and preventing osmotic lysis [64-65]. 
Echinocandin drugs noncompetitively block β-(1,3)-D-glucan synthase enzyme 
complex, targeting specifically the FsK1 subunit, disrupting fungal cell wall structure 
thereby causing osmotic imbalance and cell death [63]. 
3.3. Additional antifungal class  
Various other antifungal targets are in the market demonstrated on Figure 5 and 
Table 1. This include Polyenes like nystatin and amphotericin B which bind 
ergosterol to the cell membrane disrupting the lipidic components leading to 
development of aqueous pores in the membrane (Figure 5). As a result, the cellular 
permeability is compromised causing cytosolic component leakage and eventually 
cell lysis [66]. Flucytosine is a pyrimidine nucleoside analogue which inhibits 
thymidylate synthase disrupting DNA synthesis (Figure 5) [67]. The phosphorylated 
5-flurodeoxyuridine monophosphate is integrated into RNA thus also interfering with 
RNA synthesis [68]. Griseofulvin is a tricyclic spirodiketone which disrupts cellular 
mitosis (Figure 5). This antifungal agent interferes with spindle and generation of 





Fig. 5, The mode of action for various antifungal agents and the primary  
target. Azoles target cell membrane by blocking lanosterol 14-α-demethylase 
activity. Echinocandins inhibit cellular wall enzyme (1,3)-β-D-glucan synthase 
activity. Polyenes agents attach to ergosterol components, interfering with the 
plasma membrane of the fungi. Nucleoside analogues like, flucytosine disrupt fungal 
DNA and RNA synthesis in the nucleus. Griseofulvine disrupts the mitotic process 













Antifungal class Mode of action Antifungal drugs 










Echinocandins  Inhibit the activity of (1,3)-β-










Inhibit and disrupt DNA/RNA 
synthesis 
Flucytosine  
Antibiotic  Interfere with β-microtubulin 
during mitosis  
Griseofulvin 
 
Table 1, The antifungal classes: major molecular targets and the available 
drugs to date. 
 
4. Toxicity in prolonged antifungal therapy   
The current drugs against fungi related infections have improved significantly over 
the past few decades. However, these drugs still express high levels of toxicity. In 
[25] 
 
already immunosuppressed individuals that undergo a systemic antifungal 
treatment for a long period are subject to a higher risk of toxicity. The side effects 
related to the high toxicity lead to mild to life-threating. Itraconazole, an orally 
managed azole lead in most instances to nausea, GI irritations, and also to a rash 
which is a common side effect for most antifungal agents. Itraconazole taken with 
the oligosaccharide cyclodextrin excipient for a long-lasting treatment course of 
action becomes intolerable for the human organism [70]. in older adults, prolonged 
therapy of itraconazole results, in a triad of disorders hypokalaemia, hypertension, 
and oedema [70]. Individuals with history of heart failure and/or blood pressure 
issues are not recommended prolonged treatment with itraconazole.  
Additionally, long-lasting voriconazole therapy causes phototoxic reactions in 
association with blistering, erythema, and cheilitis [71-72]. Such reactions are not 
preventable but by discontinuing the treatment most cases are reversible with no 
additional side effects. Nonetheless, there have been growing concern that 
prolonged phototoxicity for certain individuals leads to squamous cell carcinoma 
development [71-73]. Thus, is strongly recommended that most patients should 
undergo screening for any signs of skin cancer especially if there are clear 
manifestation of photodamage reactions [72]. The antifungal agents provide short 
term effective therapy, whereas long term treatment demonstrate high rates of 







5. Antifungal drug resistance: A growing concern  
Antifungal drugs are highly effective, however, there is an increasing level of 
tolerability that Candida species and additional pathogenic yeast are expressing 
towards antifungals agents.  
5.1. Azole class mechanisms of resistance 
The leading cause in azole resistance are lanosterol 14 α-demethylase mutations 
subsequently resulting in drug-target downregulated affinity or increased generation 
or both [74]. ERG11 gene, presented in Figure 6, is responsible for encoding 
lanosterol 14 α-demethylase mutations. Fluconazole resistance, as a result of 
ERG11 mutations is most commonly associated to C. krusei resistance but is also 
suggested for C. albicans, C. parapsilosis, C. tropicalis where increased resistance 
to fluconazole are on the rise [75-76]. In C. albicans and C. tropicalis upregulation 
of lanosterol 14 α-demethylase within the fungal cell, overwhelms azole 
concentrations hence causing resistance to the antifungal drugs [74]. In addition, 
upregulation of the efflux pumps is also a factor for the prevalent of azole resistance 
[74]. Overexpression of CDR genes which encode the ATP-binding cassette (ABC) 
efflux pumps, leads in azole resistance in C. albicans, C. glabrata and C. krusei [77]. 
Upregulation of the MDR genes which encode the major facilitator (MF) efflux 
pumps, is associated only with resistance for C. albicans and C. parapsilosis [76].  
 
Susceptibility to azole drugs alternates from various Candida species. Studies have 
shown that fluconazole and voriconazole have a significantly high susceptibility of 
97% and 98.5% for C. albicans isolates. For C. tropicalis 91% and 90% are 
susceptible to for C. parapsilosis 93 and 97%, for C. glabrata 68% and 83% 
[27] 
 
respectively where susceptible to fluconazole and voriconazole [46]. C. 
guillermondii which accounts for less than 1% of candidemia cases, demonstrated 
74% susceptible for fluconazole and 91% for voriconazole [4][46]. Moreover, the 
new emergent Candida pathogen, C. auris appears to exhibit high levels of 
antifungal resistance to fluconazole and voriconazole agents, 7 and 46% 
respectively [47]. 
5.2. Echinocandins class mechanisms of resistance 
Yet similar to azoles effectiveness, Candida and other fungal species are gradually 
increasing resistance. Point mutations in FKS1 and/or FKS2 genes, seen on Figure 
6, are associated with Candida species developing echinocandin resistance [78-40]. 
Nevertheless, the precise resistance pathway is not fully understood. Prolonged 
exposure arises mutations in FSK1 gene, this phenomenon has been observed in 
C. albicans, C. glabrata, C. krusei and C. tropicalis [81]. As of yet FSK2 acquired 
mutations are only detected in C. glabrata [82]. The increasing rates of mortality and 
morbidity associated with fungal, especially Candida species infections, occurs as 








Fig. 6, The antifungal drugs resistance mechanisms.  
On the left is presented the azoles family member drugs that target cell plasma 
membrane. Mutations in ERG11 genes lead to overexpression or alternation of 
the azole target. Therefore, azole drugs do not interact with ergosterols and 
antifungal resistance occurs.  
On the right is presented the Echinocandins member drugs make their way 
through the gluco- and mannoproteins matrix, β-1,6-glucan complex integrated 
on the outer cellular wall. Mutations on FKS genes (mutations showed as  
(FSK*)), however, prevent the echinocandins to target β-(1,3)-D-glucan 
synthase. As a result, antifungal resistance arises. 
 
5.3. Drug resistance and toxicity 
Various antifungal drugs have various functions therefore, in certain instances more 
than one drug has to be administered. However, this rises another concern that is 
drug-drug interactions. Coadministration of certain antifungal drugs, such as any 
type of triazole with echinocandin drug – caspofungin, risks the possibility of low 
[29] 
 
concertation in the circulation or inhibiting each other’s metabolites causing an 
increased risk of treatment failure [86]. The development of antifungals is shackled, 
in comparison to the development of novel antibacterial drugs as, yeast are 
eukaryotic organisms sharing closely related cellular aspects to humans hence lack 
broad target for pathogen-specific antifungals [10][84]. The need to discover novel 
antifungal drugs and the understanding their mechanisms is vital for treating fungal 
infections. Very few antifungal drugs remedy IFI, many of which are significantly 
developing resistance. Consequently, there is a growing demand for novel and long 
lasting affective antifungal drugs.  
 
6. Antifungal drugs development and “the good” features  
A novel antifungal drug to enter the consumable mark into a pharmacy shelf requires 
certain features, demonstrated on Figure 7, and rigorous testing for efficacy. Firstly, 
new agents must have a broad spectrum for targeting various fungal organisms. 
The ideal antifungal agent should attack and kill development of the fungal species 
responsible for most fungal infections, including members of the Candida, 
Aspergillus, Cryptococcus, Lomentospora and Fusarium species, class family.  
Secondly, for the past decades a concern has been toxicity levels associated with 
antifungal drugs. For instance, the increased toxicity levels associated with 
amphotericin B have expressed irritations after prolonged usage. Therefore, the new 
antifungal agents have to express a much-reduced level of toxicity equal to none. 
The new drugs should be safe for a prolonged course of treatment.  
Thirdly, another important aspect of new antifungals is drug-to-drug interaction. The 
occurrence of drug-to-drug interaction could lead irritation or even organ 
[30] 
 
complications. Therefore, new antifungal drugs should have a clear mode of action 
against fungal infections and such interaction must not occur.  
In addition, the current drugs available, even though provide clear relief of 
symptoms, still remain fungistatic. Although fungistatic drugs simply inhibit the 
growth for a temporary period of time and do not to provide full clearing of infection. 
Thus, an ideal antifungal agent would be a fungicidal drug killing and further halting 
fungal contagious organ spread.  
Moreover, a new drug needs to undergo drug discovery screening and 
development. After initial essential research, compound analysis and assays, and 
in vivo investigation. If deemed safe, a period of drug discovery justification and 
candidate selection occurs. Then it proceeds into preclinical development and later 
proceed to clinical trial phases once approval by the governmental authorities is 
granted for human trails. After being safe and passes a success rate higher than 
50%, is approved by the drug administration authorities for mass production.  
Sixthly, the new antifungal should be efficient for the consumer. Therefore, oral 
administration, i.e. pill, is easier for administration rather than intravenously which is 
uncomfortable and time consuming.  
Lastly, novel antifungals have to accessible for every individual worldwide and be 
cost efficient. Drugs need to be available and at low rate price for purchase not only 





Fig. 7, The drug discovery process and the time scale for a drug to go from a 
molecular laboratory research to be filled ready for consumption.  
 
7. Introduction to the Yeast Killer Fungus  
Prof Brian Cox within the Kent Fungal Group recently identified a fungus which he 
fittingly named the Yeast Killer Fungus (YKF) due to its ability to release a metabolite 
that inhibits fungal growth in a Candida streaked-plate. This fungus was fittingly 
named as a “killer fungus”, as it secretes a compound which exhibits preferable 
antifungal properties. Previous studies conducted by Buscaino lab members, have 
identified YKF as 99.67% genomic identical to Resiniium bicolor, a fungus found in 
decayed wood [85]. Preliminary research showed YKF to have antifungal activity 
against C. albicans, but no antibacterial activity was suggested [85]. This new 
fungus also exhibits growth inhibition of C. albicans-fluconazole resistant strains. 
Importantly, in vitro characterisation using human cell lines suggested no human 
toxicity present [85]. Additionally, heat stability test showed that YKF compound is 
resistible to temperatures as high as 120°C [85]. These factors demonstrate the 





8. Aim of the thesis 
Previous research indicates that the antifungal compound generated by the Yeast 
Killer Fungus has potential for an antifungal agent. This could lead, to 
pharmacological screening and development of a future drug. During the course of 
this project the microbiological activity characteristics and biochemical properties of 
the YKF antifungal compound have been studied.  
To determine the microbiological bioactivities of the YKF compound several aspects 
were investigated. Initially, an evolutionary experiment was conducted to acquire a 
laboratory protocol for routine use. In addition, the YKF supernatant bioactivity 
towards the C. albicans and various other NCA’s, including the infectious agent C. 
auris was investigated. An important aspect of the research was the study of the 
antifungal characteristic of the YKF compound. It was pivotal to establish if the YKF 
compound is a fungicidal or fungistatic agent.  
Moreover, the secondary aim of the research was the biochemical analysis of the 
YKF compound. The goal was for the YKF compound to be purified, isolated and 
identified in order to obtain more knowledge on the antifungal compound and to use 
its concentration for microbiological investigations.  
The fungal infections are on the rise the need for new antifungals is to be addressed 
urgently. Therefore, the yeast killer fungus promises desirable features that could, 
in the near future, undergo drug discovery procedures and have a novel antifungal 





■ Methods and Materials 
 
1. YKF growth and cultivation  
The Yeast Killer Fungus (YKF) was stored in Buscaino’s lab in the cold room (4-
5°C). YKF (puffball-like shape fungal structure) was grown in YPD 1/10 liquid media 
made from yeast-extract, peptone and dextrose (Table 2). The YKF was also grown 
in solid media. Using a 1 mL pipetted, the tip of the 1 mL tip was cut to extract the 
YKF puffball from the original culture to grow it in fresh YPD 1/10 media. The YKF 
organism in the media releases the antifungal YKF compound, as shown in Figure 
8. YKF in the liquid was stored at room temperature.  
 
  
Fig. 8, The YKF supernatant. The YKF organism inoculated in fresh YPD 1/10 
liquid media. Once in the media starts to release the antifungal compound 





2. Media conditions 
i. Normal YPD liquid media. To make 200 mL YPD liquid media (also to be 
referred from this moment onwards as normal YPD) 2 mg yeast-extract, 4 mg 
bactoTM peptone, 4 mg dextrose (glucose) and 200 mL water was used. 
Various YPD media volumes were used such as 400 mL and 1 L (Table 2).  
ii. YPD 1/10 liquid media. YPD 1/10 has the same ingredients as normal YPD, 
however, tenth the amount. Therefore, for 200 mL was used 0.2 mg yeast-
extract, 0.4 mg bactoTM peptone, 0.4 mg dextrose (glucose) and 200 mL 
water (same amount as normal YPD). The same was done for different liquid 
media volumes, Table 2. 
iii. Solid media. For plates (solid media), the same amount (mg) of agar was 
added for normal and tenth YPD. However, at various overall volumes 
different amount of agar was added as seen in Table 2. 20 mL of the agar 
media was pipetted in plates during the course of the research project. 
All liquid and solid media were autoclaved before used in an experiment. 
 
Media  YPD YPD 1/10  
Liquid Volume 200 mL 400 mL 1 L 200 mL 400 mL 1 L 
Yeast extract  2 mg 4 mg 10 mg 0.2 mg 0.4 mg 1 mg 
Bacto-peptone 4 mg 8 mg 20 mg 0.4 mg 0.8 mg 2 mg 
Dextrose 4 mg 8 mg 20 mg 0.4 mg 0.8 mg 2 mg 
 Water 200 mL 400 mL 1 L 200 mL 400 mL 1 L 
Solid Agar (addition) 4 mg 8 mg 20 mg 4 mg 8 mg 20 mg 
 
Table 2. Concentrations for normal YPD and YPD1/10th in liquid or solid form. 
[35] 
 
3. Candida strains and growth conditions 
i. Candida inoculation. The Candida strains were inoculated in 5 mL 
normal YPD media in glass tubes and were incubated at 30°C for 17-20 
hours (referred on this thesis as overnight growth).  
a. Streaked-plate. From the overnight Candida inoculates 50 uL was 
diluted in 200 uL YPD 1/10 media. This 250 uL Candida culture was 
pipetted onto the plate, using a glass cell spreader the culture was 
spread all over the agar plate (Petri dish).  
b. Poured-plate. In a 50 mL falcon tube, overnight Candida inoculates 50 
uL was diluted in 20 mL YPD 1/10 agar. The falcon was centrifuged 
for the Candida strain to mix well with the agar media and then was 















ii. C. albicans and NCA isolates.  
The Candida strains Buscaino 
Lab code 
Obtained 
Candida albicans  C. albicans  (AB 55) Berman’s 
lab Non-Candida 
Albicans (NCA) 
C. guilliermondii B-3163  (AB 121) 
C. tropicalis 660  (AB122) 
C. krusei 653  (AB 123) 






C. parapsilosis  (AB126) 
C. dubliniensis* (AB 262) Myers lab 












Table 3. Candida stains used and the lab that were obtained from. 
 
 
* C. dubliniensis (AB262), strain name CdTLO1-His-FLAG, was also used. This 
strain containing a Wu284 tagged with a tandem affinity 6x His / 3x FLAG tag.  An 
M2 antibody is used for FLAG.  
 
4. YKF s/n activity and testing  
i. Disc-diffusion assay. The activity of the YKF was determined using the 
disc-diffusion assay. In a Candida culture streaked-plate, a 6 mm paper 
disc was placed in the centre. A volume of 40 μL of YKF s/n was pipetted 
in the disc paper. The plates were incubated overnight at 30° overnight. 
[37] 
 
The following day, as seen in Figure 9, a zone of inhibition (ZoI) is shown. 
This assay was the used throughout the project to test the activity. 
 
 
Fig. 9, Disc-diffusion assay procedure. YKF s/n added onto the 6 mm disc paper 
placed on the centre of a streaked-plate. After an overnight inoculation, a halo-like 
are is shown around the disc paper. This are is referred as the zone of inhibition. 
 
ii. Evolutionary experiment. Two YKF puffballs-like fungi were placed in 
two 300 mL YPD 1/10 (500 mL) flasks (total volume of 600 mL). The flasks 
were named 'YKF (R)' and 'YKF (C). The YKF supernatant from these 
cultures showed no ZoI for period of 9 day. Therefore, each flask was 
separated in two 150 mL volume YKF s/n into smaller flasks, as shown in 
Figure 10. From culture YKF (R) and YKF (C) two subcultures for each 
were created 'YKF (R. 1)': 'YKF (R. 2)' and 'YKF (C. 1)': 'YKF (C. 2)' 
respectively. The flasks 'YKF (C. 1)' and 'YKF (C. 2)' were stored in cold 
temperatures at 4-5° (Figure 10). Whereas the flasks 'YKF2 (R. 1)' and 
'YKF2 (R. 2)' were kept at 20-22°C, room temperature levels (Figure 10). 
[38] 
 
The activity and diameter of the ZoI for all four cultures was measured 
every two days.  
 
 
Fig. 10, The evolutionary experiment procedure. YKF culture was prepared, two 
flasks in 150 mL YKF s/n where stored at 4-5° (cold room temperature) and two 150 
mL flasks stored at 20-22°C temperature to observe the maximum activity against C. 
albicans for each culture.  
 
5. Growth assay to determine YKF s/n activity against C. albicans 
i. C. albicans biological replicates. Three tubes containing C. albicans 
strains were inoculated (section 3.i) for overnight growth in incubator at 
30°C. The following day 100 µL of the overnight inoculates was pipetted 
into 5 mL of normal YPD and placed in the incubator at 30°C to grow 




Fig. 11, Biological replicates of C. albicans for the growth assay.  
1.a) C. albicans strains was inoculated in 5 mL of YPD liquid media.  
1.b) C. albicans grow (over a period of 18-24 hours) in the media reaching stationary 
phase. 
2) 100 µL from each tube was taken and inoculated in fresh YPD liquid media to 
grow overnight.   
 
ii. Growth assay: 96 well plate. To determine the YKF viability 96 well plate 
was used. In each well, 100 µL of YKF s/n and C. albicans was added. 
The absorbance (OD600) of C. albicans culture inoculated the previous 
day, was measured. For each volume going in the well 7 eppendorf tubes 
containing YKF s/n and in another one with no YKF s/n just 100 µL of C. 
albicans as a control were prepared. A YKF s/n volume target was set: 
0.1 µL, 0.2 µL, 0.5 µL, 1 µL, 5 µL, 10 µL and 20 µL. 
[40] 
 
a. 96 well plate preparations. In each well 90 µL was targeted for YKF 
s/n and YPD media (YKF: YPD) whereas 10 µL for C. albicans 
overnight culture and YPD media (55: YPD).  
b. YKF s/n calculations. In each eppendorf tube, was calculated for a 
volume of 11 wells and not 9 wells per 8 rows as were needed. This 
was done in case there was spillage or laboratory error occurred. For 
example, for 1 µL YKF s/n in an Eppendorf tube 11 µL was mixed with 
979 µL YPD media. Meaning, 1 µL YKF s/n with 89 µL YPD media, a 
total of 90 µL YKF: YPD, illustrated in Figure 12. For each YKF s/n 
and media concentrations the calculations were conducted as 
demonstrated in Table 4. For 0.1 µL, 0.2 µL and 0.5 µL final amount, 
1 µL, 2 µL and 5 µL were diluted into 10 µL YPD 1/10 liquid media. 
Multiplied by 11x, hence: 11 µL YKF s/n → 110 µL YPD 1/10 media; 
22 µL YKF s/n → 110 µL YPD 1/10 media and 55 µL YKF s/n → 110 


















Table 4. The concentration of YKF s/n and YPD media in an eppendorf tube 
prior to being pipetted onto the 96 well plate. 
 
 
c. C. albicans culture calculations. A series of equations were 
conducted to determine the amount of C. albicans and normal YPD 
media needed. The absorbance of the C. albicans overnight 
inoculation was measured. This was required for a series of 
calculations shown below. Then, 50 µL of C. albicans culture was 
diluted in 450 µL of normal YPD as seen in Figure 12. This was done 
for all three technical replicates and was pipetted in the appropriate 
wells of the 96 well plate as shown in Figure 13. 
 
Equations to determine C. albicans final concentration per technical: 
Concentration in tube= OD/dilution 
Cells/µL tube = (concentration in tube X cells/µL (30,000))/1 
Cells/µL in Eppendorf = (cells/µL plate)/ 0.1= 600 
YKF s/n concentration 
per well 
YKF s/n in 
eppendorf tube 
YPD media in 
eppendorf tube 
0.1 µL 11 µL 979 µL 
0.2 µL 22 µL 968 µL 
0.5 µL 55 µL 935 µL 
1 µL 11 µL 979 µL 
5 µL 55 µL 935 µL 
10 µL 110 µL 880 µL 
20 µL 220 µL 770 µL 
[42] 
 
Vol. tube to Eppendorf = (600 X 1000)/ cells/µL tube 




Fig. 12, The volume of YKF s/n and C. albicans culture diluted into normal YPD 
before pipetted on the 96 well plate.  
a) 11 µL of YKF s/n diluted in 979 µL YPD. This is an example for 1 µL YKF s/n 
target, for various concentrations different YK s/n and YPD was used (Table 4). Final 
volume of tube 1 mL and 90 µL pipetted in the respective well.  
b) 45 µL C. albicans diluted in 450 µL normal YPD. Reaching final volume 500 µL 
and 10 µL of this mixture was pipetted onto the corresponding well of each technical 
triple replicate. 
 
d. The volumes per well. For each of the C. albicans 
technical, three replicates were conducted. 
Column: As demonstrated in Figure 13, in a group of 
three columns C. albicans diluted in normal YPD media 
[43] 
 
from that technical was pipetted. Thus, columns 1-3 
technical 1, columns 4-6 technical 2 and columns 7-9 
technical 3. Additionally, in column 10, all rows, only 100 
µL of YPD 1/10 was pipetted as a media control.  
Row: In the first raw (A), columns 1-9, only 100 µL of C. 
albicans was pipetted as a control. Additionally, for the 




Fig. 13, Illustration of a 96 well plate - the volume of YKF s/n and C. albicans (C. 
alb) in each well for three biological replicates. Three technical replicates were 
conducted. On the first row was pipetted 100 µL of C. albicans inoculated in normal 
YPD liquid media. In the rest of the of the wells various amounts of YKF s/n: 0.1 µL, 
0.2 µL, 0.5 µL, 1 µL, 5 µL, 10 µL, 20 µL, and C. albicans (55) were pipetted in each 




6. Determining YKF compound antifungal property 
i. The C. albicans inoculations in normal YPD media. An experiment 
was established to determine the YKF antifungal trait, as seen below in 
Figure 14. C. albicans strain was inoculated overnight in normal YPD at 
30°C incubator. The following day the absorbance of the C. albicans was 
measured. To reach an absorbance of approximately OD= 0.3, 150 µL C. 
albicans was inoculated into 5 mL fresh normal YPD. The OD measured 
was OD= 0.266. The new tube was placed in the incubator at 30°C for 
about 5 hour 30 minutes to reach lag phase and an OD= 0.6 
(approximately). 
ii. YKF s/n and YPD 1/10 testing. Afterwards, the OD was measured OD= 
0.676. The new C. albicans inoculate was separated in two 15 mL falcons, 
in one falcon 1 µL of YPD 1/10 liquid was added whereas in the other 
falcon 1 µL of YKF s/n was added. The falcon tubes were incubated at 
30°C incubator for 1 hour 30 minutes. The absorbance of each tube was 
measured, ODYKF = 0.412 and ODYPD = 0.508.  
iii. Spin and Wash procedure. Next, the falcon tubes were placed in the 
centrifuge at 20°C, 4000 rpm for 5 minutes. The pellet for each tube (YKF 
and YPD 1/10 tube) was collected and separated from the supernatant. 
The pellet was washed with fresh YPD1/10th liquid media and placed in 
the centrifuge. This step was repeated another time to wash the pellet 





Fig. 14, Determining YKF fungistatic and fungicidal characteristics. C. albicans 
was inoculated overnight. 150 µL was added onto 5 mL YPD liquid media, an OD= 
0.3 (approximately) was measured. After, approximately 5 hours the lag phase C. 
albicans were separated into two falcon tubes. In one tube 1 µL of YPD 1/10 was 
added whereas in the other tube 1µL of YKF s/n was added. The tubes where 
incubated at 30°C for about 2 hours. Afterwards, the falcon tubes where placed in 
the centrifuge, spun at 4000 rpm at 20°C for 5 minutes. Then the pellet was 
separated from the s/n and washed with fresh YPD 1/10 reaching a total volume of 
4 mL. This step was conducted again. Then, at various concentrations (300, 500, 
and 700 cells per plate) were spread onto the YPD 1/10 agar plates. 
 
 
iv. Calculation for C. albicans cells per plate. After, wash and spin step 
the absorbance was measured again, ODYKF = 0.394 and ODYPD = 0.508. 
There are 3 x 107 cells/mL as a result: 
ODYKF = 0.394 x (3 x 107 cells/mL) = 11’820’000 cells OR 1.182 x 107 cells 
ODYPD = 0.508 x (3 x 107 cells/mL) = 42’600’000 cells OR 4.26 x 107 cells 
[46] 
 
An end result of 300, 500 and 700 cells per plate was needed (performed five times 
per each target-cells for the YPD control and YKF s/n culture). Subsequently, an 
equation was set.  
 
YKF s/n calculation: 
0) 300 cells à 300cells/200µL (amount pipetted) = 1.5 cells/µL  
200 µL is the volume that has been used throughout the project to pipette into an 
agar plate  
1.5 cells/µL x 1000µL/1mL = 1’500 cells/mL 
1) 1.182 x 107 →1/100 dilution→ 1.182 x 105 
2) C1V1=C2V2 
1.182 x 105 x X = 1’500 cells/mL x 1 mL 
X ≈ 0.0127 mL OR 12.7 µL → C. albicans culture needed 
Therefore, 1 mL – 12.7 µL = 987.3 µL → YPD 1/10 liquid media 
1 mL is the capacity of an eppendorf tube used for this experiment. 
3) 200 µL C. albicans: media pipetted onto the YPD 1/10 agar plate 
 
YPD media calculation: 
0) 300 cells à 300cells/200µL (amount pipetted) = 1.5 cells/µL  
1.5 cells/µL x 1000µL/1mL = 1’500 cells/mL 
1) 4.26 x 107 →1/100 dilution→ 4.26 x 105 
2) C1V1=C2V2 
4.26 x 105 x X = 1’500 cells/mL x 1 mL 
X ≈ 0.0035 mL OR 3.5 µL → C. albicans culture needed 
Therefore, 1 mL – 3.5 µL = 996.5 µL → YPD 1/10 liquid media 
[47] 
 
3) 200 µL C. albicans: media pipetted onto the YPD 1/10 agar plate 
The same equation was used for 500 and 700 cells per plate for YKF and YPD 1/10 
cultures.  
 
7. Chloroform extraction  
i. Chloroform solvent addition. 50 mL of YKF s/n was added into a Duran 
bottle. In the same Duran bottle 50 mL of Chloroform (purchased from 
fisher scientific) was added. The same procedure was conducted using 
50 mL normal YPD and adding 50 mL of chloroform in another separate 
Duran bottle. The YPD: chloroform was used as a control. The Duran 
bottles were placed in the roller mixer for an hour.  
 
 
Fig. 15, The separation of phases on chloroform extraction. The YKF 
supernatant, or YKD 1/10th media, are mixed with chloroform a purer sample. Two 
phases are created, one the aqueous phase with the unnecessary media 




ii. Phase separation and resuspension. Onto a glass funnel the mixtures 
were added to collect the chloroform (organic) phase and the supernatant 
(aqueous phase), as demonstrated in Figure 15. Using the disc-diffusion 
assay the aqueous phase activity was tested whereas the chloroform 
phase collected were left in the fume cupboard (closed window) to dry 
completely for 1-2 days. After the drying out, 2 mL of chloroform was 
added in both YKF and YPD chloroform phases to resuspend.  
 
8. Thin-layer chromatography (TLC) procedures  
i. Silica paper controls.  
a. Silica paper preparations. In the silica paper 40 µL of YKF s/n and 
YPD 1/10 and the extracted YKF s/n and YPD 1/10, liquid media was 
pipetted. The silica paper was let to be dry for approximately 5 and 15 
minutes for non-extractions and extractions, respectively.  
b. Testing silica paper in poured-plate medium. After a solvent 
system was chosen (8.iii), the silica paper (for each case) was placed 
on the bottom of the plate. 10 mL of agar media was mixed with 500 
µL of C. albicans overnight inoculate and placed in a water bath at 
50°C whereas, in the meantime, 10 mL of YPD 1/10 agar media was 
added. The media from the water bath was added onto the rest of YPD 
agar on the plate. The plates were let placed in the incubator at 30°C. 
After overnight growth in the incubator the zone of inhibition diameter 





ii. TLC technique.  
a. Pre-TLC chamber preparation. In a silica paper a line was drawn to 
mark the baseline (point of origin), two dots were also drawn along the 
line one for the YKF and one for media extractions. 40 µL of each 
extraction was pipetted in the silica paper. The paper was let in the 
fume cupboard to dry for about 15 minutes. A glass 50 mL beaker was 
used as a TLC chamber.  
b. TLC chamber and assessment. The silica paper treated with a 
solvent system (8.iii) was placed into the chamber, as shown in Figure 
16, and run for approximately 10-20 minutes. Afterwards, the silica 
paper was placed on the fume cupboard to dry for about 5 minutes 
and was observed under UV light. Next, potassium permanganate 
(KMnO4)  was selected as the stain of choice. Potassium 
permanganate is a general stain that enables to detect functional 
groups that are sensitive to oxidation like, alkenes and alkynes. The 
TLC paper was dipped in potassium permanganate (KMnO4) and 
dried with a heat gun to observe the separation spots. The area where 
the spot migrated appeared in a bright yellow on a purple background.  
iii. The solvents systems used. For treatment of the silica paper to test the 
activity in a poured-plate and used as a solvent system for the TLC 
chamber various different solvents were used: DCM: hexane (2.5 mL: 2.5 
mL), DCM: 5 % methanol (4.75 mL DCM: 0.25 mL methanol), DCM: 10 
% methanol (4.5 mL DCM: 0.5 mL methanol), DCM: 15 % methanol (4.25 
mL DCM: 0.45 mL methanol), DCM: 20% methanol (4 mL DCM: 1 mL 
methanol), DCM: 25 % methanol (3.75 mL DCM: 1.25 mL methanol), ethyl 
[50] 
 
acetate (2 mL). For testing the bioactivity towards C. albicans in a poured-
plate the silica papers treated with solvents were placed in the fume 
cupboard to dry for approximately 15 minutes.  
 
 
Fig. 16, Thin-layer chromatography procedure. The TLC chamber using a 
beaker. The silica paper, containing the chloroform extraction YKF s/n and YPD 
1/10 media placed in the baseline. The polar/nonpolar solvents at the bottom is 















■ Results  
 
1. YKF antifungal components inhibit C. albicans 
Previous results from the Buscaino lab demonstrated that the Yeast Killer Fungus 
(YKF) produces an unknown compound that displays antifungal qualities. To 
determine the bioactivity of YKF supernatant towards C. albicans, a disc-diffusion 
assay was performed. Accordingly, fresh YPD 1/10 liquid media was inoculated with 
a two-month old YKF culture. The flask was stored at room temperature, for a period 
of two weeks that the YKF to release its antifungal particles into the liquid media. 
The YKF fungal organisms flouting in the YPD 1/10 liquid media start to release the 
antifungal component in the media generated the YKF supernatant (s/n). The YKF 
s/n was spotted on an autoclaved disc paper and placed on agar plates seeded with 
a loan of C. albicans cells. As a negative control a disc paper containing only YPD 
1/10 media was used. 
As shown in Figure 17, the YKF antifungal compound, evidently inhibits C. albicans 
growth as a halo-like region, clear of C. albicans cells, was created around the disc 
paper containing the YKF compound whereas for the control there no “halo” was 
visible. This halo-like area is the known as the zone of inhibition (ZoI) as it supresses 
the growth activity of microbial species i.e., C. albicans. The YKF zone of inhibition 
for C. albicans streaked-plate and poured-plate for each triplicate were on average, 
approximately 2.4 and 2.7 cm, respectively. Figure 18 demonstrates the measured 
diameter of the zones of inhibition for each triplicate. The streaked-plate provides a 
YKF activity concentrated on the surface of the plate where the fungal colonies are 
present. The poured-plate showed, that the YKF compound not only halted C. 
[52] 
 
albicans for cells grown on the surface, but also, its bioactivity permeates through 
the solid media inhibiting cells bellow surface. For either growth media type used 
the YKF compound antifungal agents inhibit C. albicans growth at an approximate 
similar level. Thereafter, the streaked-plate was used as the growth media method 
to proceed in additional experiments as an efficient laboratory procedure.  
 
 
Fig. 17, Control and YKF activity in C. albicans streaked-plate and poured-
plates. (A) normal YPD liquid media pipetted used as a control. (B) YKF ZoI in C. 
albicans mixed with agar, poured-plate growth medium. (C) YKF activity in C. 






Fig. 18, The diameter of the YKF s/n ZoI on C. albicans for different agar 
growth media. The C. albicans streaked onto the 1/10th YPD agar plate showed a 
slight lower ZoI. In comparison, the C. albicans: 1/10th YPD poured-plate media 
showed a larger “halo” in diameter. The halo-like area around the disc containing 
YKF, zone of inhibition, was measured for each triplicate. The error bar represents 
the average standard deviation (SD) of three biological replicates.  
 
 
2. YKF compound inhibits growth of Non-Candida Albicans 
To assess whether the YKF is a broad spectrum compound  its activity was tested 
towards additional Candida species commonly referred as Non-C. albicans (NCA). 
The NCA used for this experiment were the Candida species that are largely 
associated with candidemia and phylogenetically closely related to C. albicans such 
as, C. guilliermondii, C. tropicalis, C. parapsilosis, C. dubliniensis, C. krusei, and 
four C. auris (Figure 19). Additionally, the non CTG clade fungal pathogen, C. 




Fig. 19, Phylogeny of the C. albicans and the Non-C. albicans strains. C. 
albicans, C. tropicalis, C. dubliniensis, C. parapsilosis are members of the Candida 
genus, and share a close ancestry with C. guilliermondii. C. auris, and C. krusei 
belong to more distant phylum sharing a much further distant ancestor. All belonging 
to the CTG clade. C. glabrata, however, is closer associated with S. cerevisiae, 
belonging to WGD node. This figure represents only the Candida species used on 
this project in comparison to the previous image (Figure 1). S. cerevisiae is 
presented in this image as a comparative yeast between C. glabrata and the other 
Candida.  
 
The YKF compound activity was analysed using a disc-diffusion assay. Onto the 
micro-filter paper YKF s/n was added on an agar streaked-plate with NCA species. 
YKF compounds inhibit growth of the NCA used as a halo-like area is created 
around the YKF-injected filter disc in comparison to the YPD negative control that 
showed no such area (Figure 20/A). It was expected that C. tropicalis, C. 
parapsilosis, C. dubliniensis, as these fungi share taxonomic family and genes 
[55] 
 
with C. albicans to display similar reaction to the YKF antifungal components. The 
diameter of YKF inhibitory activity for both C. glabrata isolates was approximately 
3.9 cm (Figure 20/B and 20/C). The members of the Candida genus showed an 
inhibitory diameter of 3.2 cm for C. tropicalis (Figure 20/D), 3.8 cm C. parapsilosis 
(Figure 20/G) and 3.1 cm for C. dubliniensis (Figure 20/H). C. krusei and C. 
guilliermondii an inhibitory area of approximately 2.7 cm and 3 cm respectively 
was shown (Figure 20/E and F). 
Surprisingly the four C. auris strains used also demonstrated a reasonable hale-like 
region. These strains collected from clinical isolates from different countries. C. auris 
strains DMS 21092 and JCM 15448 isolates were collected from Japan, as shown 
in Figure 20/J and K, with a zone of inhibition diameter of approximately 2.6 cm and 
2.0 cm respectively. The C. auris strains KCKC 17809 and KCKC 17810 collected 
from South Koran hospital isolates, had a diameter of about 1.7 cm and 2.5 cm, 
respectively (Figure 20/L and M). Although these C. auris strains were collected 
from different hospitals in different countries they presented a relatively good area 
of inhibition, hinting to the YKF compound antifungal strength towards a diverse 
family of pathogenic Candida species. It was observed similarly to C. albicans, YKF 






Fig. 20, YKF activity on C. albicans and NCA strains.  
First row: YPD control (A) and Non-C. albicans (NCA): C. glabrata L5 (B), C. 
glabrata BG2 (C), C. tropicalis (D) 
Second row: C. krusei (E), C. guilliermondii (F), C. parapsilosis (G) and. C. 
dubliniensis (H) 
Third row: C. auris strains, DMS 21092 (J), JCM 15448 (K), KCKC 17809 (L), KCKC 
17810 (M).  
This experiment was conducted in triplicate.   
  
3. The evolutionary antifungal activity of the YKF s/n 
Identifying the time period, the YKF s/n reaches the maximum antifungal activity 
towards C. albicans was crucial. Knowing the exact point in time, the YKF s/n 
reaches full antifungal potential is important to establish a robust protocol that could 
[57] 
 
be used for all future experiments. In order to determine the strength of the YKF 
supernatant activity, an evolutionary experiment was performed. Therefore, two 
original YKF cultures were separated into four flasks containing YKF grown in YPD 
1/10 media. These four cultures were cultured in parallel, two were placed at 4-5°C 
and two at room temperature. Every two days, for a period of 38 days, YKF samples 
from each culture was tested and the diameter of the ZoI was measured using the 
disc-diffusion assay.  
As expected, at time 0 (t=0), when YKF fungal organism was added onto YPD media 
no zone of inhibition was visible. On day 2 a halo-like region was observed for both 
YKF (R. 1 and R. 2) culture incubated at 20-22°C (Figure 21). It was observed that 
YKF (R. 1) and YKF (R. 2) showed, every 2 days a relatively similar area of 
inhibition, both reached maximum strength on the same time and both started to 
deteriorate on a similar fashion. After two days both demonstrated a ZoI of a 
diameter of roughly 2 cm. These cultures reached maximum strength on day 14. 
The ZoI diameter of YKF (R. 1) and YKF (R. 2) were 2.5 and 2.6 cm, respectively. 
In room temperature the supernatant bioactivity starts to decline causing their 
antifungal strength to weaken. 
In comparison, on day 2 the YKF cultures stored at 4°C expressed no zone of 
inhibition on the C. albicans. On day 4, one of the cultures incubated at 4°C started 
to show a zone of inhibition with a of less than 1 cm. The YKF C. 1 was unfortunately 
contaminated. The YKF s/n stored at 4-5°C (YKF C.2) showed a slow increase in 
its antifungal activity strength. Nonetheless, on day 34 it reached its strongest 
antifungal activity, demonstrated in Figure 21, with a ZoI diameter of 3.6 cm.  
[58] 
 
This experiment although conducted using in two parallel cultures was only 
performed once, with no additional replicates. This could have occurred because 
YKF cellular division in warmer and colder temperatures differs. As the YKF (C. 1) 
was contaminated, the data for YKF s/n incubated at 4-5°C should be interpreted 
with a degree of caution.  
The curve and the maximum strength, illustrated in Figure 22, in terms of diameter, 
for the YKF antifungal potency. As seen in Figure 22, the antifungal activity strength 
for all YKF cultures started to decrease thus the experiment was stopped after 38 
days. Therefore, the YKF s/n reaches it maximum activity for cold and room 
temperature, on day 14 and day 34, respectively. This was key to establish the 
highest antifungal strength at two different temperature settings. Subsequently, all 
other experimental aims were conducted using the room temperature YKF s/n at the 




    
Fig. 21, The evolutionary experiment set to determine the YKF’s antifungal 
strength.  
Day 0: the day YKF culture inoculated on the YPD 1/10 media showed no area of 
inhibition.  
Day  2: room teperature YKF cultutres (R. 1 and R. 2) shows ZoI. 
Day 14: YKF R. 1 and R. 2 reaches peak antifungal activity. After day 14 both room 
temperature stored cultures start to degrade.  
Day 34: YKF C. 2 (4-5°C) reaches maximum antifungal activity.   
Day 38: The evolutionar experiment was concluded. YKF (C. 2) was contaminated 




Fig. 22, A graphical representation of the YKF s/n antifungal strength against 
C. albicans. The (x) axis represents the time frame and the (y) axis the diameter of 
the antifungal ZoI in centimetres. YKF (R. 1) and YKF (R. 2) reach maximum activity 
on day 14 whereas YKF (C. 2) reaches its hights antifungal activity on day 34.  
 
4. Increasing YKF s/n volume inhibits C. albicans growth 
So far it was established that the YKF inhibits the growth of C. albicans in a streaked-
plate medium. However, to have a better understanding of the YKF interaction with 
C. albicans a growth assay experiment was performed. A 96 well plate was used in 
order to determine the minimal volume of YKF s/n necessary to inhibit C. albicans 
growth. It is important to note that on these experiments are used different volumes 
of YKF s/n with an unknown concentration of YKF antifungal compound. Increasing 
the amount (from 0.1 µL to 20 µL) of YKF s/n taken from a two-week old culture, 
was incubated with C. albicans liquid culture in a 100 µL final volume. A culture 
containing C. albicans with no YKF s/n was used as a control.  
[61] 
 
This experiment demonstrates that with increasing the YKF s/n volume the C. 
albicans cells do not grow (Figure 23). This suggests that the YKF at higher volume 
inhibits, the growth of C. albicans. As observed in Figure 24/A & B, the lower 
amounts used in this experiment, 0.1 µL and 0.2 µL of YKF s/n have no effect in the 
C. albicans growth. Their curve dispersion resembles the curve of the control 
(black). The log phase initiates at approximately 7 hours and reach stationary stage 
at about 15 hours, remaining stable for the rest of the plate reader measurement. 
YKF s/n at 0.2 µL, unlike with the rest of the amounts, was run in duplicates and not 
in triplicate.  
It is visible that at 0.5 µL of YKF s/n, as seen in Figure 24/C, the growth of C. albicans 
is inhibited for approximately 20 hours and then steadily begins to increase. As the 
volume of YKF s/n increases it can be observed that C. albicans takes longer to 
grow. For YKF s/n 0.5 µL and 1 µL the log phase lasts for approximately 17 hours 
and afterwards beings to steadily increase (Figure 24/E). YKF s/n at 5 µL stalls C. 
albicans growth for nearly 30 hours, reaching exponential phase after 30 hours.  For 
YKF 10 µL the log phase of C. albicans lasts for nearly 40 hours for as long as it 
was run in the plate reader. From the data represented in the graph at 40 hours 
there is a slight increase on the curve signalling C. albicans emerge growth (Figure 
24/F). In comparison, at 20 µL YKF the growth of C. albicans is inhibited and as 
seen in Figure 24/G, there is no significant increase on the curve (light orange). It 
appears that C. albicans remain in log phase for the entire period the plate reader 
was run indicating that YKF s/n increase in volume may not only has an inhibition 




Fig. 23, Graphical representation of the YKF s/n viability against C. albicans. 
Various volumes of YKF s/n were used to determine its antifungal activity by 
inhibiting C. albicans growth. This graph presents the control run with no YKF (black 
curve), and 0.1 and 20 µL of YKF s/n (the lowest and highest volumes used). The 
error bars show the average SD of the three biological replicates. 
 
Figure 24, demonstrates the individual graphs for the control and the biological 
replicates for each YKF increased volume, illustrated with error bars. Error bars 
represent the variability and impreciseness of the data, using standard deviation 
equation in excel. Standard deviation expresses any error or differentiation in the 
data represented in the graph.  
The error bares for the biological replicates of YKF 0.2, 0.5 and 10 µL are higher as 
the log phase initiates (Figure 24). This could be as such phase, for various technical 
replicates could have initiated earlier or later in time hence the irregularities in the 
error bars. Nevertheless, it does not compromise the evidence that by increase the 




Fig. 24, Graphical illustration of all biological techincals for the control with 
all YKF volumes. The biological replicates of volume increase of YKF interaction 
with C. albicnas with the control (black). On the left is shown: 0.1 µL (A), 0.2 µL (B) 
and 0.5 µL (C) YKF s/n. On the right is shown: 1 µL (D), 5 µL (E), 10 µL (F) and 20 




5. Antifungal characteristics of the YKF compound   
A vital concern regarding antifungal agents is the YKF compound characteristic. An 
ideal antifungal drug would be a fungicidal agent.  Therefore, it is essential to 
determine if the YKF compound expresses fungistatic, ability to inhibit fungal growth, 
temporarily, or fungicidal, kills fungal microorganisms. Therefore, an experiment 
was set to determine such YKF compound antifungal traits.  
An overnight inoculated C. albicans culture was diluted in YPD liquid media and was 
placed in the incubator. When the culture reached log phase was separated into two 
falcon tubes (Figure 14). In one tube YKF was added and in another falcon YPD 
1/10 which was used as a control. The tubes where incubated again at 30°C to reach 
early lag phase.  
 
Following washes, the cultures with the YKF and YPD 1/10 media were spread onto 
plates with the aim to pipette 300, 500 and 700 C. albicans cells per plate. This 
experiment was conducted five time for designated amount of C. albicans colonies 
per plate. This was conducted to ascertain the YKF compound antifungal 
characteristics when the cells amount increases.    
The C. albicans colonies, incubated over night at 30°C, were counted manually. 
From the count, it was observed that the C. albicans cells treated with YKF, were 
significantly less in number as the ones treated with YPD 1/10, as seen in Figure 
25. Calculating the percentage of YKF treated colonies against YPD 1/10 treated 
colonies, demonstrated in Table 5, only 34-39% of C albicans grew. These results 





Table 5, The cells counted for YKF and YPD 1/10 treated C. albicans, the percentage 
YKF/YPD and the sum for each quintuple.    
 
 
Fig. 25, A graphical representation the C. albicans culture treated with YKF 
s/n and YPD media. The 300, 500 and 700 colony unites were aimed to be 
pipetted onto YPD 1/10 agar plates. The bars demonstrate the number of C. 
albicans cells grown. C. albicans treated with YKF s/n are shown in yellow 
whereas the ones treated with YPD 1/10 media (control) shown in green. The 




300 500 700 
  YKF YPD YKF/YPD 
(%) 
YKF YPD YKF/YPD 
(%) 








34 230 15% 73 403 18% 120 319 38% 
66 149 44% 132 375 35% 120 408 29% 
67 145 46% 180 308 58% 123 404 30% 
65 167 39% 155 335 46% 145 448 32% 
46 127 36% 108 247 44% 155 366 42% 
Sum 55.6 163.6 34% 129.6 333.6 39% 132.6 389 34% 
[66] 
 
These results demonstrate that approximately 40% of C. albicans continue to grow. 
These could either indicating that YKF compound is not fully fungicidal and could 
have some fungistatic characteristics, or a larger concentration of the YKF 
compound would be required. Nonetheless, considering that 1 µL YKF kills the vast 
majority, about 60%, of C. albicans, YKF has desirable fungicidal traits. As most C. 
albicans cells are shown to have died out, these results suggest that the YKF 
compound is a fungicidal agent rather than fungistatic. 
 
6. Biochemical approach of the YKF compound 
Isolating and identifying the antifungal component of the YKF is a key aspect of the 
research project. Fractionation techniques where modulated to purify the YKF 
supernatant and isolate the antifungal agent. The YKF supernatant activity was 
investigated using silica paper. This was conducted to determine the YKF 
supernatant is absorbed by the silica paper hence to later proceed with Thin Layer 
Chromatography (TLC) technique. Onto the silica paper was added YKF 
supernatant pre-chloroform extraction, contained in the optimal environment, and 
the organic phase YKF s/n that underwent chloroform extraction. In Figure 26/B i. 
and ii. is demonstrated pre-extraction and extracted chloroform phase YKF s/n. 
Either expressed a reasonable ZoI of 1.6 cm and 2.5 cm respectively. Pre- and post-
chloroform extracted YPD 1/10 liquid media, displayed on Figure 26 A i and ii, were 
also conducted as a negative control. For both, YPD media controls no halo-like 
region was observed.  
Additionally, the chlorform phase of the YKF and the YPD media, as a control, were 
added onto the silica paper. The silca paper was treated with various polar and non-
[67] 
 
polar chemicals employed, as a mobile phase for th TLC experiment used to 
determine the YKF compound. The mobile phase should habe the ability to migrate 
an analyte organic material. The silica paper was treated with lower methanol, 
respectively, 2%, 5%, and 10% in 5 mL dichloromethane (DCM). After run on a thin-
layer chromatography chamer, the silica paper was empolyed with potassium 
premanganate to dipict the separated spot. As shown on Figure 27/a, b, c, decresing 
the concentration of the very polar substance demonstrated that for eithier YKF or 
YPD particles did not move through the paper but remianed on the baseline. This 
could suggest that the YKF compound is realtivly a more polar agent. As a result, 
the concetration of the more polar methnaol was increased to 15%, 20% and 25% 
in 5 mL of DCM. It was observed, as is seen in Figure 27/d, e, and f, that both the 
YKF and YPD particles moved to the front (top) of the paper. 
 
Furthermore, the silica paper was treated with with pola:non-polar reagents as a 
solvent system. Dichlormethane (DCM) was employed as a moderatley polar 
solvent was mixted with the non-polar hexane in a 1:1 ratio. Similarly to the other 
solvents employed DCM:hexane solvent system, demonstrated in Figure 27/g, no 
YKF compound spot was visiable. The TLC plate was also treated with ethyl 
actetate, a very polar solvent showen on Figure 27/h. Neverthless, this addetive also 
did not expressed no spot separation or difference between the YFK agent and the 
YPD media. The similarity of the YKF supernatant and the control YPD media, as 
observed in all the silica TLC experiments, is atributed to the fact that the YKF 
surpantant is composed of the same media components as the control YPD media. 
Both contain yeast estract, bactopetone and glucose.  
[68] 
 
As none of the TLC bioassays revealed any spots, additionally techniques would 
have been attempted. However, due to time restrictions because of COVID19 
pandemic lockdown, this experiment was halted to a stop hence opening the scene 
to speculative scrutinisation (further interpretation on the following section: 
Discussion: Part. 6).   
 
        
Fig. 26, YKF supernatant activity observed using silica paper.  
A) pre- (i.) and post-extraction (ii.) activity of the YPD 1/10 liquid media.  
B) pre- (i.) and post-extraction (ii.) activity of the YFK supernatant. The YKF presents 
the reasonable zone of inhibition before and after undergoing chloroform extraction. 
The halo-like area for B)i. suggests that the YKF compound is in the chloroform 





Fig. 27, TLC paper treated with methanol and Dichloromethane (DCM).  
Moderately: very polar solvents: by decreasing the polar levels of methanol (very 
polar) in 5 mL DCM (moderately polar), 0/2% (a.), 0.5% (b.) and 10% (c.) methanol 
the YKF compound does not move from the baseline. In comparison, increasing the 
polarity, 15% (d.), 20% (e.) and 25% (f.) methanol in 5 mL DCM the YKF compound 
moved to the solvent front (the top).  
Moderately polar: non-polar solvents: 2. 5 mL of DCM (non-polar additive) mixed 
with 2. 5 mL hexane (moderately polar) demonstrated no spot separation (g). There 
was a bright yellow resembling a line from baseline to the silica paper front for both 
YKF and YPD media (not quite visible on the picture).  
Very polar solvent: using only the very polar 2mL ethyl acetate (h) as a solvent 
system also showed no spot separation.  
 
A mass spectroscopy of the YKF supernatant was run to analyse the YKF 
compound composition. The analysis of the chloroform extracted YKF compound 
[70] 
 
on positive ion mode electrospray ionization mass spectrometry (ESI-MS) displayed 
a range of ion peaks. Minor peaks are presented at m/z 846.4513, 663.4586, 
432.2439, in addition to other lesser peaks , as seen on Figure 28. The highest ion 
peak (base peak) detected was 415.2174 m/z (mass-to-charge ratio value) 
presenting the most intensively abundant ion fragments. The antifungal compound, 
however, is not isolated from the TLC experiment, this cluster of molecules is not 
pure. Therefore, to obtain insight on the molecular structure from the MS analysis, 
the exact mass data of the highest peak is placed in a mass database, named: 
massbank.eu. This provides a degree of speculative insight to examine the unknown 
antifungal compound. As demonstrated in Table 6, several agents share a closely 
related exact mass with the base peak of the mass spectrometry. Tomatidine 
exhibits 50 spectra in comparison to the other components. This data does not 
suggest that the YKF antifungal compound is tomatidine but could indicate to a 







Fig. 28, Mass spectrometry of the non-purified YKF chloroform phase. The 
highest peak detected is at 415.2174 m/z at x104 relative intensity. This exact mass 
data was placed in the massbank.eu website shown on Table 6.  
 
Name Formula Exact Mass 
Acemetacin 
25 spectra 











Table 6, the data produced form the massbank.eu website presenting the most 
closely related compound to the data from the mass spectrometry front peak.  
  
An NMR of the YKF s/n was conducted to observe the chemical properties of the 
compound. The NMR presents the chemical shift through depicting the protons. The 
furthest shift observed, Figure 29, is at 7.3 ppm (parts per million). This indicates 
the presence of an aromatic substance with a hydrogen at the phenyl group. The 
other proton peaks at about 0.9 ppm suggest alkyl (methyl) and smaller peak at 1.5 
detects the presence of an alkyl methylene (Figure 29). The peak at approximately 
[72] 
 
2.5 ppm is an indicative to an alkynyl present in the composition (Figure 29). The 
larger peak at about 0 ppm simple suggest background noise and solvents used for 
NMR preparation. The MS and NMR spectroscopy research were run by Dr Gary 
Robinson at University of Kent. 
 
 
Fig. 29, NMR spectroscopy analysis of the YKF s/n. The NMR data shows the 
chemical shift of the protons. The most distant chemical shift at 7.3 ppm could 
indicated to an aromatic compound. Other nearer to 0 axis implies the presence of 









■ Discussion   
 
In this work, microbiological and biochemical approaches were utilized to study the 
antifungal properties of compound secreted by the Yeast Killer Fungus. 
1. Fungal Infections: A Global Problem  
Fungal infections account for some of the most difficult human diseases to manage. 
Fungal-related disease occur in healthy individuals but the most considerably they 
manifest in severe illness, jeopardizing medical treatment for other serious diseases 
[1]. Fungal infections led to reduced quality of life for billions of individuals worldwide 
and the numbers of fungal infections are increasing every year [2]. Candidemia, 
caused by the Candida family yeast are one of the most sever invasive fungal 
infections [15]. New emerging pathogenic fungi like, the recently characterised 
organism C. auris that is able to evade drug therapy targets are making it harder for 
affected individuals to receive effective medical treatment [54]. In addition, there is 
an eminent global concern regarding an increase in fungal drug resistance. Azoles, 
echinocandins and other antifungal drug therapies do not provide the most effective 
treatment for fungal infections not only for the serious pathogenic organism C. auris 
but also for the most common fungal pathogen, C. albicans. Therefore, the need for 
development of new, effective and safe antifungal agents is critical.  
 
2. The Yeast Killer Fungus (YKF) secretes an antifungal compound   
Previous work conducted from Prof Brian Cox and the Buscaino laboratory (within 
Kent Fungal Group) has identified a fungus named Yeast Killer Fungus (Resinicium 
[74] 
 
bicolor). The YKF fungus secrets in its culture media a compound that expresses 
antifungal activity. 
 
3. Establishing a protocol to reliably test the YKF compound activity 
YKF secretes over time an antifungal compound in its media culture. To date the 
antifungal activity nature of the YKF compound remains unknown. Therefore, any 
research aimed at understanding its antifungal properties cannot be conducted as 
the compound was not purified, concentration remains unknown, but it is conducted 
using the volume of YKF cell culture media known as supernatant. In this culture 
media, the concentration of YKF compound in the supernatant is likely variable and 
it will accumulate over time. 
One of the first aims of my thesis research was to establish a robust protocol to test 
YKF s/n antifungal properties. My priority was to identify the optimal window in order 
to “harvest” the YKF s/n and test its activity. Therefore, I performed an evolutionary 
experiment and established that YKF s/n reached maximum activity 14 days post 
inoculation, when grown in 20-22°C. After 14 days the YKF compound begins to 
degrade as the antifungal strength of YKF s/n is reduced. On the other hand, the 
activity of the YKF s/n cultivated in cold room temperatures (4-5°C) takes 34 days 
to reach full antifungal potential. Even after a few days it continues to retain it 
antifungal strength to stop the growth of C. albicans cells. Under low temperatures 
the killer fungus maintains its morphological and biochemical form, therefore, the 
process of degradation takes a longer period of time. It was concluded that the ideal 
time to use the YKF s/n was after a period of 14 days since YKF culture inoculation 
[75] 
 
in media. This procedure would be used for additional experiments until the YKF 
compound is purified and concentration is known.  
 
4. Candida genus species are susceptible to the YKF compound 
Work presented in this thesis demonstrates that YKF compound is active not only 
against the C. albicans but also against other Candida species. Indeed, YKF 
compound stopped the growth of C. dubliniensis, C. tropicalis, C. parapsilosis and 
C.  guilliermondii. Importantly, YKF compound is also active against the recent 
emerging pathogen C. auris. This is key due to C. auris multi-drug resistant (MDR) 
fungal pathogenic trait. C. auris develops resistance for azoles due to point 
mutations in the lanosterol 14 α-demethylase gene, and upregulation of the ERG11 
and the efflux pump genes. Five single-nucleotide polymorphisms (SNPs) in 
different genome loci and FKS1/2 gene mutations cause C. auris resistance for 
polyenes and echinocandin drugs, respectively. As a result of this mutations C. auris 
is resistant to approximately 60% of azole drugs, 15% of the polyene, amphotericin 
B, and less than 2% of the caspofungin. Accordingly, caspofungin drugs are 
currently used as the first-line for C. auris infections treatment management [54]. 
These factors make C. auris a dangerous fungus in the human body and difficult to 
treat. Therefore, YKF compound could provide an antifungal window for  the MDR 
C. auris infections therapy and treatment. The four C. auris clinical isolates obtained 
were susceptible to the YKF antifungal compound. This is a landmark as C. auirs is 
difficult to treat and is highly resistant to the current antifungal drugs available.  
Unexpectedly further distant organisms such as, C. krusei or C. glabrata 
demonstrated susceptibility to the YKF agents. C. krusei belongs to the Pichiaceae 
[76] 
 
family part of the CTG clade whereas, C. glabrata along with Saccharomyces 
cerevisiae are categorised members of the Saccharomycetaceae family part of the 
WGD clade. Both strains of C. glabrata showed a large area of inhibition thereby 
exhibit high sensitivity to the antifungal agents of the killer fungus.  
Consequently, the YKF displays a broad spectrum of antifungal activity towards C. 
albicans, the Candida species of the CTG clade, to the pathogenic MDR C. auris, 
and to the WGD clade yeast C. glabrata.   
 
5. Fungicidal VS Fungistatic features of the YKF compound  
An ideal antifungal drug must kill the human pathogenic fungi in order to prevent 
invasive fungal infection prolonged treatments and the high levels of toxicity which 
would be as damaging to human tissues as the fungal infection itself. Unfortunately, 
the current antifungal drugs in the market are fungistatic. These drugs treat fungal 
infections by inhibiting pathogenic fungal species growth and development by 
keeping them at bay. Therefore, work to develop and identify fungicidal agents 
which kill the infectious fungi is persistent.  
Experiments demonstrated in this thesis show that YKF compound is a fungicidal 
component. The YKF compound showed to kill approximately 60% of the C. 
albicans cells. The ability that YKF s/n did not perform 100% killing could be due to 
several reasons. The main factor for such performance could be because the 
concentration of the YKF compound is unknown. The YKF component concentration  
on the supernatant volume could not have been enough to kill the C. albicans cells. 
Therefore, until the YKF compound is purified and isolated the concentration needed 
to kill 100% of the C. albicans remains unknown and impossible to speculate at this 
[77] 
 
point. Another factor that could have played a role in not showing a total killing of 
the C. albicans could have been due to degradation of the YKF compound. Although 
throughout the project YKF s/n used was 2 weeks after inoculation the culture media 
could have begun degrading faster. Changes in the required optimal room 
temperature could have caused such property. Nevertheless, the results obtained 
are very promising for future work once the compound is purified and characterised. 
This research presents that the Yeast Killer Fungus secreted compound exhibits a 
desirable fungicidal trait for an effective antifungal agent.   
 
6. Biochemical processes and limitations 
One of the main goals of this project was to isolate and identify the Yeast Killer 
Fungus compound by utilizing biochemical approaches. Unfortunately, these 
experiments were not completed due to governmental and university COVID-19 
pandemic lockdown rules. The biochemical investigation and additional 
microbiological aims were promptly stopped. Such limitations and additional 
research needed are discussed on part 7: ‘Further studies’.  
 
The mass spectroscopy (MS) analysis presented that most spectra, 50 spectra, 
corresponded to the glycoalkaloid compound tomatidine. This steroidal alkaloid is 
mostly observed as a plant-derived alkaloid synthesised in tomato leaf hence the 
name tomatidine. Glycoalkaloids are known to have antimicrobial activity to protect 
the plant from microbial infections [86]. Tomatidine has be presented to express 
bacteriostatic effect on certain bacteria such as, Staphylococcus aureus SCVS [87]. 
There have been additional studies that suggest glycoalkaloids, especially 
[78] 
 
tomatidine antimicrobial activity against the simple yeast S. cerevisiae, and 
importantly to this thesis, towards a few Candida species. A study has shown that 
tomatidine is highly susceptible to C. albicans and C. krusei but expressed no 
activity against C. glabrata [88]. This, however, as it is demonstrated in this thesis, 
is not the case for the YKF compound which has demonstrated to kill Candida 
species growth, including C. glabrata. Although the YKF compound investigated 
utilizing MS analysis is not purified and isolated from the supernatant, nevertheless, 
the antifungal compound could be a derivative of tomatidine, or a closely related 
chemical component.  
Although at this point, we are unable to identify the YKF could be a derivative of 
tomatidine or there can be more than one compound determining the antifungal 
properties. The MS analysis also presented 25 and 6 spectra for acemetacin and 
zamifenacin, respectively. Both these components are synthetic drugs. Therefore, 
the MS data could indicate that there may be more than one antifungal agent 
present. Considering the fact that there was no compound separation in the TLC 
experiment does suggest two or more agents exhibiting antifungal property.  
 
The mixture of DCM with methanol as a solvent system suggested that by increasing 
the methanol concentration the unknown antifungal compound was observed to 
migrate to the baseline of the TLC plate. This indicates that the antifungal compound 
shows to be relatively more of a polar compound. However, to have had a better 
overview other solvent system should have been employed. The solvents used 
could have also been a factor that no spot was observed in the TLC silica paper. 
During the mobile phase, the chemical solvents used were selected as general 
[79] 
 
solvent system used often in chromatography separation. DCM, methanol, hexane, 
ethyl acetate could simply not be able to cause any separation of the unknown 
antifungal YKF compound.  
 
The limitation with biochemical aspect was due to time restrictions. Therefore, other 
methodology techniques would have been performed to determine and identify the 
YKF compound.  
Chloroform used for the biomolecular extraction procedure could have interacted 
with the solvent mixture system chosen for the TLC. Dimethyl sulfoxide (DMSO) 
could have been used as an alternative molecular extraction technique. In addition, 
other additives that could have been attempted for the solvent system including very 
polar additives such as, ethanol or isopropanol; or moderately polar solvents like, 
acetonitrile, diethyl ether, toluene; with non-polar solvents such as, pentane 
petroleum ether, cyclohexane. As DCM is a general, although moderately polar 
additive and methanol is stronger polar solvent, either a non-polar compound could 
be used or a different moderately polar solvent. Nonetheless, a variety of solvent 
systems mixtures could have provided a different outline of the TLC plate.  
 
Additionally, another reason that spot separation did not occur could have been 
because of the dye system used. The potassium permanganate (KMnO24) dye 
which was used to stain the silica gel paper could have been the issue. Potassium 
permanganate is a general stain used widely as the first-choice to depict the TLC 
particle separation. However, there are several other staining reagents which could 
have presented different data. Potassium permanganate is commonly used as it 
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detects oxidation sensitive alkenes and alkynes groups. As the NMR presented a 
spike at approximately 7.5 ppm indicating an aromatic agent hence an iodine dye 
could be used. Iodine is one of the oldest staining methods used for compound 
visualization and could have provided the compound isolation needed. 
Phosphomolybdic acid (PMA) stain, referred as a “universal” stain is another 
staining method. PMA is good for most functional groups and is sensitive to 
solutions in low concentrations. Other stains that could be used are morin hydrate 
and vanillin which are general staining tests, ninhydrin which is excellent for 
detecting amino acids, dinitrophenylhydrazine (DNP) is mainly used for aldehydes 
and ketones, Dragendoff’s reagent which provides good results for plant derived 
alkaloids, cerium sulphate which is also a general stain but is particularly developed 
alkaloids, and ceric ammonium sulphate specifically effective for vinca alkaloids 
(aspidospermas). Therefore, the TLC silica paper could have been employed with 
several excellent staining agents that could have provided a separation spot of the 
YKF compound.  
 
Additionally, issues could have been the thin layer chromatography technique. Other 
separation and isolation chromatography techniques could have been used. High 
performance liquid chromatography (HPLC) could have been used. HPLC is a 
versatile and currently gaining popularity as a robust analytical technique. 
Separation occurs by exploiting the compound’s different rate of migration [89]. 
During this technique detectors have to be chosen for compound identification. UV 
detectors are highly sensitive thus sensing small particles, or MS could be used to 
detect ionisation [89]. Moreover, phytochemical screening assay (PSA) is a simple, 
inexpensive and robust method for plant compound identification. Phytochemicals 
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are plant derived chemicals regularly described as secondary metabolic particles in 
plants [89]. Phytochemicals are found in tomato plants, as well as the glycoalkaloid 
tomatidine. Speculating that YKF compound could be a component secreted by a 
plant thus the PSA technique could provide additional insight.  
 
The concentration of the YKF supernatant could have been an issue. The inability 
to show any spots could have be to the fact that for every silica TLC a certain 
volume, 40µL, was used. The concentration of the YKF compound on the 
supernatant volume could not have been enough. There may not have been enough 
YKF molecules concentrated within the sample to be able to separate from the rest 
of the supernatant or to be depicted in the TLC paper.  
 
Changes in pH could cause the YKF compound in the supernatant to undergo 
structural alterations. The antifungal particles in the liquid culture media are 
continuously subject to the outer environmental conditions. Fungal species are 
known to modulate the pH in order to adjust a better continues living environment 
for themselves. This could have been as result of its interactions, not only with 
chloroform but with other solvents. This conditions such as alternations in the 
optimal pH could have led to its inability to show in a silica TLC. Subsequently, 
further studies need to be conducted on the biochemical aspect to purify and identify 






7. Further studies  
Further research into the biochemical trait of the YKF compound are required in 
order to examine the antifungal compound. It is essential for the YKF compound to 
be purified and isolated. Once such stage occurs, the purified YKF compound to be 
tested in vitro on C. albicans and the other NCA fungi’s used on this project. The 
characterisation experiment that showed that YKF compound is fungicidal to C. 
albicans should be test for the same NCA fungi used on this thesis. Determining if 
YKF compound is fungicidal or fungistatic would be particularly interesting for WBG 
clade C. glabrata and the pathogenic C. auris. Additional antimicrobial studies using 
various other fungi such as, the opportunistic pathogenic moulds of the Aspergillus 
family, or other species that cause fungal-related deaths, like Cryptococcus.  These 
fungi, along with Candida species account for approximately 90% of all fungal 
infections related fatalities [1][90]. Candida accounts for most invasive fungal 
infections, Aspergillus is the most common mould infection, and the Cryptococcus 
is the most prevalent fatal fungal-related disease globally. Therefore, the ability that 
YKF agent could inhibit or even kill the growth of such species would be landmark 
for antifungal drug research. A broad range of fungal targets is required for all new 
antifungal drugs hence it would provide an interesting outline for YKF compound 
spectrum activity. 
 
The YKF natural agent to be tested in combination with other existing antifungal 
agents. Neither in previous work nor in this project, combinations of YKF s/n with 
current antifungal drugs, such as fluconazole, has not been conducted, this would 
provide interesting results as many fungal infections are managed in drug pairs. 
[83] 
 
Most antifungal drugs are known to interact quite well with one-another to target 
pathogenic fungi. Interestingly, it has been suggested that tomatidine expresses 
stronger antifungal results in combination with fluconazole [88][91]. Therefore, YKF 
compound in combination with fluconazole could also provide stronger antifungal 
results. However, this interaction should be observed to determine the ability to 
cause drug-to-drug interaction which could lead to toxicity. Antifungal drugs when 
administered for long periods of time cause toxicity leading to epithelial cells organ 
damage. This could be tested in vitro but the better understanding of such toxic 
mechanism would be in vivo using model organisms. 
Subsequently, an import investigation would be to test in vivo the YKF compound 
antifungal bioactivity towards Candida species. The simple model organisms, C. 
elegans or, the fruit fly Drosophila melanogaster, would be infected with C. albicans, 
and/or other Candida pathogens. Later, to be treated with YKF either in the 
supernatant form (if not purified) or using the molecular compound (if purified). This 
would provide a clear spectrum of understanding of the YKF mechanisms in vivo. 
Additionally, mammalian model organism such as, mice would provide a better 
understanding of the YKF’s activity. Testing in laboratory fungal infected mice would 
deliver the best results for the molecular activity of YKF compound as, mice share 
85% genome similarity with humans.  
 
Additionally, as drug resistance is a significant concern for the current antifungal 
agents this is an aspect worth identifying. Although, it could be difficult to determine 
resistance, experiments could be designed to observe such phenomenon. An 
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antifungal target with the abilities to evade the known resistance mode of action or 
other pathway could be a landmark for antifungal therapy.  
As the antifungal agent generated by the YKF was not isolated further work needs 
to be conducted. A variety of other dyes could have been used. A different dye 
staining system could provide a separation spot on the TLC. Therefore, if a spot is 
present in the silica TLC paper, the spot area would be scraped off and extracted, 
using solvents such as methanol. Later a disc-diffusion assay to be conducted to 
observe its direct effect on C. albicans and other NCA species. If a zone of inhibition 
is present the next course of action would be an MS analysis to determine the 
molecular agent/s expressing the desirable antifungal properties.  
 
In conclusion  
Fungal infections cause difficult manged infections, with some being life-
threatening. The increase of fungal resistance to the available limited antifungal 
drugs, is adding to the global concerns. Luckily, the Yeast Killer Fungus provides 
hope for the future. That is supported by the susceptibility of C. albicans  and several 
other Candida species to the YKF’s antifungal component. Interestingly, even the 
newly recognized and highly pathogenic C. auris is vulnerable to the YKF 
compound. Additional studies on the biochemical activities of the YKF compound 
would provide a clear picture to its antifungal properties. Nevertheless, the YKF 
compound delivers a novel and broad range action, traits ideal for a future antifungal 
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